[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.196.37. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
May 2012

Ustekinumab for Pyoderma Gangrenosum

Author Affiliations

Author Affiliations: Institute of Clinical Medicine and University of Helsinki and Department of Dermatology, Allergology, and Venereology, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.

Arch Dermatol. 2012;148(5):655. doi:10.1001/archdermatol.2012.78

I read with great interest the article by Guenova et al,1 who showed a biological “proof of concept” with an increase expression of interleukin (IL)-23 in a pyoderma gangrenosum (PG) lesion before initiating ustekinumab therapy successfully. A wide number of local and systemic treatments have been tried for this difficult condition and, in the era of biological agents, new, targeted therapies are promising.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×